Cargando…

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice

Major depressive disorder (MDD) is a recurrent, chronic, and devastating disorder leading to serious impairment in functional capacity as well as increasing public health care costs. In the previous decade, switching therapy and dose adjustment of ongoing antidepressants was the most frequently chos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Changsu, Wang, Sheng-Min, Lee, Soo-Jung, Jun, Tae-Youn, Pae, Chi-Un
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chonnam National University Medical School 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543152/ https://www.ncbi.nlm.nih.gov/pubmed/26306301 http://dx.doi.org/10.4068/cmj.2015.51.2.66

Ejemplares similares

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises
por: Pae, Chi-Un, et al.
Publicado: (2014)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice
por: Lee, Kyung Ho, et al.
Publicado: (2020)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Experiences and barriers to implementation of clinical practice guideline for depression in Korea
por: Yang, Jaewon, et al.
Publicado: (2013)

Pain and Depression: A Neurobiological Perspective of Their Relationship
por: Han, Changsu, et al.
Publicado: (2015)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder
por: Pae, Chi-Un
Publicado: (2014)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman, Robert M, et al.
Publicado: (2011)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review
por: Richardson, J Don, et al.
Publicado: (2011)

Retrospective Case Series of Aripiprazole Augmentation in Pervasive Developmental Disorders
por: Kim, Yeni, et al.
Publicado: (2010)

Evidence-Based Treatment for Depressive Disorder
por: Pae, Chi-Un
Publicado: (2015)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder
por: Amerio, Andrea, et al.
Publicado: (2018)

A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders
por: Jeon, Sang Won, et al.
Publicado: (2017)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Does Age at Onset of First Major Depressive Episode Indicate the Subtype of Major Depressive Disorder?: The Clinical Research Center for Depression Study
por: Park, Seon-Cheol, et al.
Publicado: (2014)

Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder
por: Di Salvo, Gabriele, et al.
Publicado: (2020)

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
por: Nelson, J. Craig, et al.
Publicado: (2014)

Clinical Significance of the Number of Depressive Symptoms in Major Depressive Disorder: Results from the CRESCEND Study
por: Park, Seon-Cheol, et al.
Publicado: (2016)

Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study
por: Delle Chiaie, Roberto, et al.
Publicado: (2011)

Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report
por: Fornaro, Michele, et al.
Publicado: (2008)

Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder
por: Seo, Eun Hyun, et al.
Publicado: (2023)

Relationship between Depression and Laryngopharyngeal Reflux
por: Joo, Young-Hoon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8ud28vseem4uv948gi49knk2ak